Herpangina Treatment Market is Projected to Grow Expeditiously: to Reach $2.63 Billion by 2029

 Backed by rigorous analysis and deep industry knowledge, this study is designed to support growth and investment decisions in the herpangina treatment market.

How Much Is The Herpangina Treatment Market Worth?
The herpangina treatment market size has grown strongly in recent years. It will grow from $1.86 billion in 2024 to $1.96 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to viral outbreaks and prevalence, pediatric population growth, healthcare infrastructure development, public health awareness programs, clinical research and treatment advancements

The herpangina treatment market size is expected to see strong growth in the next few years. It will grow to $2.63 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to emerging viral strains, increasing focus on pediatric health, international health regulations, technological innovations in diagnostics, healthcare access improvements. Major trends in the forecast period include development of topical therapies for oral lesions, integration of telemedicine for diagnosis and consultation, enhanced patient education and awareness programs, collaborations for clinical trials and research, global health preparedness initiatives.

Get your free sample today:
Herpangina Treatment Market Report 2025

What Are The Current Leading Growth Drivers For Herpangina Treatment Market?
The increase in the number of research and development activities is expected to propel the growth of the herpangina treatment market going forward. Herpangina is a viral illness that usually affects youngsters, creating painful sores or ulcers on the tonsils and back of the throat caused by coxsackievirus and enteroviruses. Herpangina therapy helps to reduce the severity of herpangina symptoms such as blisters, high fever, discomfort in the mouth or throat, drooling, and loss of appetite. For instance, in April 2024, according to the Office for National Statistics, a UK-based national statistical institute, in 2022, the UK government's net expenditure on research and development rose by 10.5%, reaching £15.5 billion ($19.5 billion), compared to £14.0 billion ($17.7 billion) in 2021. Therefore, the increase in the number of research and development activities is driving the growth of the herpangina treatment market.

Which Segment Accounted For The Largest Herpangina Treatment Market Share?
The herpangina treatment market covered in this report is segmented –

1) By Treatment: Topical Anesthetics, Ibuprofen Or Acetaminophen, Other Treatments
2) By Virus: Coxsackie Virus A, Coxsackie Virus B, Enterovirus 71, Echovirus
3) By Symptoms: High Fever, Sore Throat, Blisters Or Ulcers In The Throat Mouth, Difficulty Swallowing, Loss Of Appetite, Neck Pain, Swollen Lymph Glands, and Headache
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:
1) By Topical Anesthetics: Benzocaine, Lidocaine, Other Anesthetics
2) By Ibuprofen or Acetaminophen: Ibuprofen, Acetaminophen, Other Treatments
3) By Antiviral Medications: Corticosteroids, Supportive Care

What Are The Key Trends And Market Opportunities In The Herpangina Treatment Sector?
Development of treatments for herpangina diseases such as aphthous stomatitis is a key trend gaining popularity in the herpangina treatment market. Major companies operating in herpangina treatment are developing therapies for relieving pain for people suffering from recurrent mouth ulcers. For instance, in September 2022, Mucocort, a Sweden-based healthcare company that develops oral patches, signed a deal with Aurena Laboratories AB, a Sweden-based medical technology company, and created a unique self-absorbing pain relief patch. This unique patch treatment helps people suffering from recurrent mouth ulcers and aphthous stomatitis to relieve their pain and speed up the natural healing process of the aphthous ulcer.

Which Are The Top Companies To Hold The Market Share In Herpangina Treatment Market?
Major companies operating in the herpangina treatment market include Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc, AstraZeneca, Novartis AG, GlaxoSmithKline Plc, Merck & Co., Inc., AbbVie Inc., Eli Lilly and Company, Bayer AG, Sanofi, Bristol-Myers Squibb Company, Johnson & Johnson, Mucocort, Aurena Laboratories AB, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Zydus Cadila, Aurobindo Pharma Ltd., Lupin Limited, Glenmark Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Sandoz International GmbH, Endo International plc, Mylan N.V., CSL Limited.

View the full herpangina treatment market report here:
Herpangina Treatment Market Report 2025

Which Region Is Projected To Account For The Largest Share Of The Herpangina Treatment Market?
North America was the largest region in the global herpangina treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herpangina treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Contact Us:

The Business Research Company

Market Research Reports

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: The Business Research Company | LinkedIn